Hyphens Pharma International - Phillip Securities 2025-08-25: Bump In The Road, Scaling Up Journey Intact

• Hyphens Pharma's 1H25 earnings were below expectations. Revenue and PATMI were 44%/42% of our FY25e forecast. Excluding the combined S$4.1mil losses from exchange translation and provision for ageing inventory, adjusted PATMI declined 21% y-o-y to S$5mil.
• - Read this at SGinvestors.io -

The Positive

Improving cash flow.

• Free cash flow (FCF) in 1H25 improved to S$6.2mil. A massive swing from the negative S$3.3mil FCF due to lower investments in intangibles and S$17mil swing in inventories.
• Hyphens Pharma remains in a net cash position of S$9.5mil.

The Negative

Vietnam overstocking in the near term.

• - Read this at SGinvestors.io -

Outlook

• Read more at SGinvestors.io.

Above is an excerpt from a report by Phillip Securities Research.
Clients of Phillip Capital may be the first to access the full PDF report @ https://www.stocksbnb.com/.

Read also Phillip's most recent report:
2026-03-05 Hyphens Pharma - Hit The Refresh Button.

Price targets by other brokers at Hyphens Pharma Target Prices.

Listing of research reports at Hyphens Pharma Analyst Reports.

Relevant links:
Hyphens Pharma Share Price History,
Hyphens Pharma Announcements,
Hyphens Pharma Dividend Payout Dates & Corporate Actions,
Hyphens Pharma News